PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
19.48%
Revenue growth at 50-75% of CSIQ's 36.70%. Martin Whitman would worry about competitiveness or product relevance.
32.65%
Gross profit growth similar to CSIQ's 30.01%. Walter Schloss would assume both firms track common industry trends.
66.29%
Positive EBIT growth while CSIQ is negative. John Neff might see a substantial edge in operational management.
66.29%
Positive operating income growth while CSIQ is negative. John Neff might view this as a competitive edge in operations.
77.71%
Net income growth at 50-75% of CSIQ's 109.99%. Martin Whitman would question fundamental disadvantages in expenses or demand.
75.00%
EPS growth at 50-75% of CSIQ's 106.25%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
62.50%
Diluted EPS growth at 50-75% of CSIQ's 106.25%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
7.66%
Share reduction more than 1.5x CSIQ's 35.92%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
6.47%
Diluted share reduction more than 1.5x CSIQ's 36.11%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
44.62%
OCF growth of 44.62% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
-188.13%
Negative FCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
28.93%
AR growth well above CSIQ's 13.95%. Michael Burry fears inflated revenue or higher default risk in the near future.
20.88%
Inventory growth well above CSIQ's 13.66%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
4.08%
Asset growth well under 50% of CSIQ's 15.24%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-4.55%
We have a declining book value while CSIQ shows 46.81%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
Our R&D shrinks while CSIQ invests at 215.03%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
24.49%
SG&A declining or stable vs. CSIQ's 240.54%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.